Reported Earlier, Rapport Therapeutics Prices Initial Public Offering Of 8M At $17/Share
Portfolio Pulse from Benzinga Newsdesk
Rapport Therapeutics has priced its initial public offering (IPO) of 8 million shares at $17 per share.
June 07, 2024 | 7:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rapport Therapeutics has set the price for its IPO at $17 per share for 8 million shares, indicating strong investor interest and potential for stock price movement.
The pricing of the IPO at $17 per share suggests strong demand and investor confidence in Rapport Therapeutics. This is likely to result in positive short-term price movement as the stock begins trading.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100